Disclosed are means and methods of treating major depressive disorder and/or other disorders that predispose to suicide by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells. In one embodiment said nutraceuticals are comprised of green tea extract, and/or Nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiment's nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.

The present disclosure relates to a method for producing an oral disintegrating film by a 3D printing technology which utilizes a hot-melt pneumatic extrusion method, and when a mixture including a poorly soluble drug, a film-forming polymer, and a plasticizer confirmed in the present disclosure was produced as an oral disintegrating film using the production method of the present disclosure, it was confirmed that the production method was simplified because the production process became one process, the production costs were decreased, and a poorly soluble drug having a problem in that bioavailability deteriorated due to an existing low solubility could obtain excellent solubility.

The production method of the present disclosure that solves these problems can be utilized for many poorly soluble drugs, and thus can be widely utilized as a new method of utilizing a poorly soluble drug in the pharmaceutical field.

A wearable device 100 for managing alcohol-driven violence is disclosed. The device 100 comprises a capsule C1 adapted to sense sweat of wearer and detect a level of alcohol in the sweat, a capsule C3 adapted to convert a data detected by the capsule C1 to generate signal activating a capsule C4, a capsule C2 adapted to provide power to the capsule C3, and a capsule C5 adapted to detect a muscle activity of the wearer, wherein the capsule C4 is adapted to inject a drug into the body of the wearer, when activated, and wherein the capsule C5 alerts authorities when no muscle activity is detected.

A wearable device 100 for managing alcohol-driven violence is disclosed. The device 100 comprises a capsule C1 adapted to sense sweat of wearer and detect a level of alcohol in the sweat, a capsule C3 adapted to convert a data detected by the capsule C1 to generate signal activating a capsule C4, a capsule C2 adapted to provide power to the capsule C3, and a capsule C5 adapted to detect a muscle activity of the wearer, wherein the capsule C4 is adapted to inject a drug into the body of the wearer, when activated, and wherein the capsule C5 alerts authorities when no muscle activity is detected.

Methods for detecting psychotic disorders such as but not limited to schizophrenia or bipolar I disorder featuring administering to a patient a dose of an antipsychotic medication; and subjecting the patient to an evaluation at a time point following administration of the dose of the antipsychotic medication. The evaluation is adapted to determine responsiveness or sleepiness (or amount of sleep) resulting from the dose of the antipsychotic medication.

Methods for detecting psychotic disorders such as but not limited to schizophrenia or bipolar I disorder featuring administering to a patient a dose of an antipsychotic medication; and subjecting the patient to an evaluation at a time point following administration of the dose of the antipsychotic medication. The evaluation is adapted to determine responsiveness or sleepiness (or amount of sleep) resulting from the dose of the antipsychotic medication.

The present disclosure provides methods of treating COVID-19 by administering a pharmaceutical composition providing inhibition of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (M.sup.Pro) in a patient. The disclosure also provides other methods as well as pharmaceutical formulations for use in treating COVID-19 patients.

The present disclosure provides methods of treating COVID-19 by administering a pharmaceutical composition providing inhibition of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (M.sup.Pro) in a patient. The disclosure also provides other methods as well as pharmaceutical formulations for use in treating COVID-19 patients.

The invention relates to novel compounds which are inhibitors of the ribosome protein chaperone activity (“protein folding activity of the ribosome” or “PFAR”). More particularly, the invention relates to their use as PFAR-inhibitors, to compositions comprising them and to methods for treating proteinopathies.

The invention relates to novel compounds which are inhibitors of the ribosome protein chaperone activity (“protein folding activity of the ribosome” or “PFAR”). More particularly, the invention relates to their use as PFAR-inhibitors, to compositions comprising them and to methods for treating proteinopathies.